Matthew Luchini analyst

Currently out of the existing stock ratings of Matthew Luchini, 61 are a HOLD (39.35%), 94 are a BUY (60.65%).

Matthew Luchini

Work Performance Price Targets & Ratings Chart

Analyst Matthew Luchini, has had 46.43% of price targets met with an average potential upside of 22.21%, reached in 310 days on average. Previously, Matthew Luchini worked at BMO.

Matthew Luchini has documented 303 price targets and ratings displayed on 31 stocks. The coverage was on Healthcare, Industrials, Energy, Technology sectors.

Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.

Wall Street Analyst Matthew Luchini

Analyst best performing recommendations are on ONCE (SPARK THERAPEUTICS).
The best stock recommendation documented was for ONCE (SPARK THERAPEUTICS) on 8/6/2018. The price target of $60 was fulfilled within 1 day with a profit of $17.61 (22.69%), with a performance score of 226.9.

Average potential price target upside

AGTC Applied Genetic ALXN Alexion Pharmaceuticals APLS Apellis Pharmaceuticals ARVN Arvinas BLUE Bluebird bio CCCC C4 Therapeutics GILD Gilead Sciences ICPT Intercept Pharmaceuticals IFRX InflaRx N.V. KOD Kodiak Sciences MDGL Madrigal Pharmaceuticals NG NovaGold Resources NGM NGM Biopharmaceuticals REGN Regeneron Pharmaceuticals TCRR Tcr2 Therapeutics ONCE Spark Therapeutics DBTX Decibel Therapeutics JSPR Jasper Therapeutics ETTX Entasis Therapeutics Holdings REPL Replimune Group AGLE Aeglea Bio Therapeutics BOLD Audentes Therapeutics MITO Stealth BioTherapeutics Corp ALDR Alder BioPharmaceuticals RGLS Regulus Therapeutics LIFE aTyr Pharma AG First Majestic Silver Corp AL Air Lease ET Energy Transfer LP VKTX Viking Therapeutics BL Blackline

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 11-Feb-2015

4 years 22 days ago
(25-Oct-2022)

2/13 (15.38%)

$13.99 (348.88%)

660

Hold Since 25-Oct-2022

$0.4

4 years 22 days ago
(25-Oct-2022)

1/1 (100%)

$0.01 (2.56%)

2

Hold Since 24-Oct-2022

$0.34

4 years 23 days ago
(24-Oct-2022)

0/5 (0%)

$-0.05 (-12.82%)

Buy Since 09-Feb-2017

$9

4 years 23 days ago
(24-Oct-2022)

0/3 (0%)

$7.17 (391.80%)

Buy Since 11-Nov-2020

$11

4 years 1 months 18 days ago
(29-Sep-2022)

0/2 (0%)

$6.72 (157.01%)

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?